Archive

Diagnosis and self-help for ovarian cancer

Written by Christine Clark | 17 Mar 2022

It is a complete myth that ovarian cancer is a silent killer – even early-stage disease causes symptoms and knowing what they are is key to early treatment,… read more.

Ovarian cancer – facts and symptoms

Written by Christine Clark | 16 Mar 2022

Two thirds of UK women with ovarian cancer are diagnosed late when the cancer has spread and is difficult to treat. IMI spoke to Dr Sharon Tate, Head… read more.

Initial treatment choice for prostate cancer doesn’t affect mental health outcomes

Written by Charlie King | 13 Mar 2022

Depression and other mental health outcomes are similar for men choosing different options for initial treatment of localized prostate cancer, reports a study in The Journal of Urology®, an… read more.

Women dying of ‘ignorance’ as ovarian cancer crisis continues

Written by Christine Clark | 8 Mar 2022

March is ovarian cancer awareness month and 8th March is international women’s day – a good day to call for greater awareness, early diagnosis and prompt treatment of… read more.

Ovarian cancer in a nutshell

Written by Christine Clark | 1 Mar 2022

No fewer than 11 women die of ovarian cancer every day in the UK, equivalent to more than 4000 per annum.1 About 7,500 women are diagnosed with ovarian… read more.

Sandoz launches generic lenalidomide in 19 countries across Europe

Written by Charlie King | 26 Feb 2022

Sandoz has announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest European Society for Medical Oncology (ESMO) guidelines. The… read more.

Patients with rare skin cancer face 40% recurrence rate

Written by Charlie King | 26 Feb 2022

Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40% — markedly higher than the recurrence rates for cand other skin cancers, according to… read more.

Adjuvant darolutamide prolongs survival in metastatic, hormone-sensitive prostate cancer

Written by Bruce Sylvester | 25 Feb 2022

Researchers from a phase 3 clinical trial report that addition of the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy significantly prolongs the survival of men with metastatic,… read more.

Three-drug combination prolongs survival in men with metastatic, hormone-sensitive prostate cancer

Written by Charlie King | 24 Feb 2022

Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men… read more.

Lab results show promise for future pancreatic cancer treatment

Written by Charlie King | 13 Feb 2022

University of Illinois Chicago researchers have developed a compound that may one day offer hope for pancreatic cancer treatment. A pre-clinical study of the experimental compound shows that… read more.

New treatment emerges for difficult-to-treat form of ovarian cancer

Written by Bruce Sylvester | 9 Feb 2022

Trametinib, a drug treatment for skin and lung cancers, appears to slow the progression of low-grade serous cancer of the ovary and to increase the number of patients… read more.

Phase III IMpower010 study of Tecentriq consistent with previous studies in NSCLC and published in The Lancet – Genentech/Roche

Written by Charlie King | 8 Feb 2022

Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS)… read more.

« Previous 1 … 14 15 16 17 18 … 37 Next »

Archive

Subscribe for our mailing list

Follow Us